G-KnowMe Partners With University Of Cambridge

Bangalore-based G-KnowMe has partnered with researchers at the University of Cambridge and the Cambridge University Hospitals NHS Foundation Trust to create an automated workflow for interpreting cancer genome sequencing data.

Genome sequencing has significantly improved our understanding of cancer at an individual level, providing valuable insights for treatment and novel treatments. However, the availability of structured information, compiling relevant pieces and staying updated on emerging updates pose significant challenges to adopting genome sequencing in the clinic. This is due to the need for a structured method for processing and interpreting this vast amount of scientific information.

Genome sequencing (NGS) is becoming the new paradigm in cancer management due to its cost-effectiveness and scale. However, timely interpretation of data is a challenge. The Precision Breast Cancer Institute at the University of Cambridge plans to develop a clinical interpretation of WGS data for breast cancer patient management. 

Professor Jean Abraham, Director of the Precision Breast Cancer Institute, emphasised the need for cutting-edge automation and artificial intelligence-powered natural language processing tools to achieve this at scale. The collaboration aims to extract maximum patient-relevant information for better disease management.

G-KnowMe is partnering with Indian diagnostics labs to develop solutions for cancer treatment. The G-KnowMiner platform is already used to interpret NGS panels for cancer diagnostics. The partnership aims to expand its scope to interpreting WGS data within a clinically relevant time frame. Tumor profiles can personalise treatment plans, predict response or resistance to therapies, suggest off-label therapies and identify inherited cancer factors. The goal is to improve cancer management through the use of large panels.